Lucid Diagnostics wins Concert coverage policy for EsoGuard esophageal DNA test across client health plans

Reuters2026/08/05 12:47

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Lucid Diagnostics secured a commercial coverage policy from Concert for its EsoGuard esophageal DNA test, effective July 2026.
Concert cited published guidelines and peer-reviewed evidence, classifying EsoGuard as medically necessary for patients meeting ACG screening criteria.
Multiple Concert client health plans have adopted the policy, expanding potential reimbursement access across those plans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608050846PR_NEWS_USPR_____NY19812) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Lucid Diagnostics wins Concert coverage policy for EsoGuard esophageal DNA test across client health plans

You may also like

Crypto prices